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Comparison of acute rapamycin nephrotoxicity with cyclosporine and
FK506. Acute cyclosporine (CsA) nephrotoxicity is characterized by a
reduction of glomerular filtration rate (GFR), hypomagnesemia and
tubular injury. The mechanisms of CsA's immunosupprcssive action and
presumably its nephrotoxicity are mediated through inhibition of the renal
phosphatase, caleineurin. FK506 (FK), which has a different chemical
structure and binding immunophilin, also inhibits calcineurin. We com-
pared the renal effects of these drugs to those of rapamycin (RAPA),
which although similar in structure and intracellular binding to FK, does
not work by changing calcineurin activity. Rats were given CsA (15
mg/kg/s.c.), FK (6 mg/kg/p.o.), RAPA (3 mg/kg/p.o.) or vehicle (V) for two
weeks on a low salt diet. CsA and FK strikingly decreased urinary
excretion of nitric oxide, renal blood flow and GFR, whereas RAPA did
not. In contrast, all these three drugs caused significant hypomagnesemia
associated with inappropriately high fractional excretion of magnesium,
suggesting renal magnesium wasting. In addition, with all three drugs
there were lesions in the rat kidneys consisting of tubular collapse,
vacuolization and nephroealeinosis. We thus showed that only the cal-
cineurin inhibitors produced glomerular dysfunction in an acute experi-
mental model of nephrotoxicity. The mechanism of hypomagnesemia and
tubular injury induced by all three immunosuppressive drugs is unclear but
may be independent of calcineurin. The mechanism of renal vasoconstric-
tion on the other hand may be related to inhibition of ealeineurin.
Cyclosporine A (CsA) has played a large role in the improve-
ment in solid organ transplant graft survival rates. Thus indica-
tions for the drug are being extended to the treatment of
autoimmune and primary renal diseases [I]. However, the neph-
rotoxicity of CsA continues to be a major problem [2, 3]. Acute
CsA nephrotoxicity is characterized by a decrease in glomerular
filtration rate (GFR) and renal blood flow (RBF), hypomag-
nesemia and tubular injury [4]. The mechanism and mediators of
these hemodynamie and structural changes are yet to be defined,
and possible links between functional changes and structural
damage remain to he elucidated. Hypomagnesemia has been
implicated in the pathophysiology of neurotoxicity and essential
hypertension [5]. Hypomagnesemia is common in transplant
patients receiving GsA and has been proposed as an important
factor in the pathogcnesis of CsA nephrotoxicity [6]. FK506
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(tacrolimus, FK) and rapamycin (sirolimus, RAPA) have also
been used clinically to treat transplant rejection [7, 81; in addition,
they have been useful agents in helping to define the mechanisms
of immunosuppression and nephrotoxicity with this class of drugs.
Despite structural differences, CsA and FK inhibit T-lymphocyte
activation by a similar mechanism, namely, through inhibition of
the renal phosphatase calcineurin, while CsA and FK bind to
different families of intracellular binding proteins immunophilins
[9]. RAPA has a distinct mechanism of action, despite being
structurally homologous to FK and binding to the same immu-
nophilin. RAPA does not inhibit ealcineurin [10]. Recently, Lea et
al reported that CsA and FK reduced Na,K-ATPase activity in
medullary thick ascending limb (mTAL) through inhibition of
ealeineurin with the same potency as the drugs inhibit IL-2
transcription in T cells, while RAPA did not [11]. Na,K-
ATPase in the kidney might be linked to active magnesium
transport in tubules. Preliminary data indicate that RAPA shows
considerably less nephrotoxicity than CsA and FK [12, 131. The
purpose of this study is to compare the effects of these structurally
and pharmacologically different immunosuppressants, on renal
tubular and glomerular dysfunction to gain insights into whether
CsA nephrotoxicity is mediated through inhibition of renal phos-
phatase calcineurin or if nephrotoxieity can be dissociated from
the immunosuppressive actions of these drugs.
Methods
Animals
Male Sprague-Dawley rats (Charles River, Wilmington, MA,
USA) weighing 225 to 250 g were housed in individual cages in a
temperature- and light-controlled environment. They received a
low salt diet (0.05% sodium; Teklad Premier, Madison, WI, USA)
and were allowed free access to tap water. They were weighed and
examined daily.
Drugs
CsA, provided by Sandoz Research (East Hanover, NJ, USA),
was diluted in olive oil and subcutaneously given to animals at 15
mg/kg/day. FK (Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan)
was provided in a solid dispersion vehicle formulation, dissolved
in distilled water and orally given to animals at 5 mg/kg/day.
RAPA, obtained from Wyeth-Ayerst Research (Princeton, NJ,
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USA), was dissolved using a dilution of Tween 80 (10%), N-N-
dimethylacetamide (20%), and polyethylene glycol 400 (70%) and
orally given to animals at 3 mg/kg/day. The control animals were
received the same formulation of vehicles of those three drugs.
Design of experiments
After one week on low salt diet with ad libitum tap water,
weight-matched pairs of rats were randomly assigned to receive
CsA 15 mg/kg, FK 6 mg/kg, RAPA 3 mg/kg or an identical volume
of vehicles (VH) for 14 days. The doses of these drugs were
chosen from published data reporting the same potency for
immunosuppression [14—16]. The numbers of pairs for each
experimental groups were determined by the number of desig-
nated measurements (8 rats for each measurement of GFR and
RBF or perfused kidney, respectively). The vehicle, FK and
RAPA rats were pair fed to the amount of food consumed the day
before by the CsA rats. On day 14 tail blood pressure (BP) was
measured with a plethysmography (Natsume Seisakusyo, Tokyo,
Japan) and the rats were placed in metabolic cages (Nalge
Company, Rochester, NY, USA) for urine collection. The urine
was collected into a plastic tube cooled with ice. After 24 hours
the animals were anesthetized with intraperitoneal ketamine and
a blood sample was drawn. At this point, as previously designated
for each rat, GFR and RBF were measured by 14C-inulin clear-
ance and a blood flow probe, or one kidney was collected for
histology after in vivo perfusion.
Inulin clearance and RBF
After anesthesia with intraperitoneal ketaminc (50 to 100
mg/kg), a polyethylene catheter (PE-50) was inserted into the left
carotid artery and connected to a digital blood pressure analyzer
(World Precision Instruments, Inc., Sarasota, FL, USA) for
continuous measurement of the mean arterial blood pressure and
heart rate. The animal's cavity was opened with a midline incision
and the left renal artery was carefully exposed, and a transit-time
blood flow probe (Transonic Systems, Inc., Ithaca, NY, USA;
model 1RB) was placed around the vessel. The flow probe was
connected to a small animal, digital transit-time blood flow meter
(model T106, Transonic Systems, Inc.). Other polyethylene tubes
(PE-50) were placed in the jugular vein for blood collection and in
the femoral vein for infusion of solutions. A polyethylene tube
(PE-90) was placed and sutured in the bladder. A heating lamp
was positioned above the animal to maintain the body tempera-
ture. A loading dose of 0.25 jxCi '4C-inulin (NEN Research
Products, Wilmington, DE, USA) in 6 ml 1% NaHCO3 was given
followed by a maintenance infusion of 2.5 ftCi 14C-inulin in 10 ml
1% NaHCO3 at a rate of 52 j.tl/min using a pump (Harvard
Bioscience, South Natic, MA, USA). After a 30-minute equilibra-
tion time, urine was collected over four periods of at least 20
minutes each in preweighed vials. A blood sample (0.30 ml) was
drawn at the midpoint of each urine collection and replaced with
an equal volume of 1% NaHCO3. Fifty microliters of urine from
these samples were placed in a scintillation vial to measure
radioactivity with a Beckman LS 3801 liquid scintillation counter
(Beckman Instruments Inc., Palo Alto, CA, USA). The blood
sample was centrifuged and a 100 d aliquot of the plasma was
placed into a scintillation vial for measurement of '4C radioactiv-
ity by liquid scintillation. Inulin clearances values expressed as
ml/min/100 g body wt represent the mean of the four clearance
periods. After the end of the inulin clearance the animal was
sacrificed and the left kidney was weighed. GFR was represented
for both kidneys and calculated per 100 grams of body wt by the
standard formula.
Histology
After anesthesia a ventral midline incision was made exposing
the abdominal aorta, posterior vena cava and renal vessels. The
aorta and vena cava, just above the bifurcation to the iliac and the
mesenteric arteria were tied. A ligature was loosely tied around
the aorta and vena cava above the left renal artery. An 18-gauge
needle was introduced in the abdominal aorta pointing toward the
kidneys. An infusion of 20 ml of saline with 500 U of heparin was
started simultaneously as the ligature above the left renal artery
was tied and a hole was made in the left renal vein. After the
saline flush, six minutes of perfusion with 1% glutaraldehyde in a
modified 3/4 Tyrode buffer was done by using a pump. The
pressure in the system was kept stable at 140 to 160 mm Hg and
the flow at 10 to 12 mI/mm. After perfusion fixation the left kidney
was emersed in the same fixative for 24 hours, following which it
was washed in cold Tyrode solution for 24 hours. Multiple
transverse sections of the kidney were processed and embedded in
paraffin. Two to four micron-thick sections were stained with
periodic acid-Schiff stain and examined by light microscopy by an
observer (DCH) masked to treatment groups. The histological
findings were subdivided into two categories: tubular injury and
nephrocalcinosis. Finding ascribed to tubular injury included
cellular and intercellular vacuolization; tubular collapse (unasso-
ciated with interstitial fibrosis or tubular basement membrane
thickening) and tubular distention. The extent of changes in
cortical tubules was graded according to the following criteria:
Score 0, no tubular injury; Score 0.5, < 5% of tubules injured;
Score 1, 5 to 20% of tubules injured; Score 1.5, 21 to 35% of
tubules injured; Score 2, 36 to 50% of tubules injured; Score 2.5,
51 to 65% of tubules injured; Score 3, > 65% of tubules injured.
Nephrocalcinosis was defined as the presence of calcium crystals
within the tubular lumen and was primarily found at the cortico-
medullary junction. Nephrocalcinosis was semiquantitatively as-
sessed using the following scoring system: Score 0 no nephrocal-
cinosis present; Score 0.5, < 5% of tubules in corticomedullary
junction; Score 1, 5 to 10% of tubules in corticomedullary junction;
Score 1.5, 11 to 15% of tubules in corticomedullary junction; Score 2,
16 to 20% of tubules in corticomedullary junction; Score 2.5, 21 to
25% of tubules in corticomedullaiy junction; Score 3, > 25% of
tubules in corticomedullary junction.
Magnesium supplementation
After one week on low salt diet with ad libitum tap water,
additional weight-matched pairs of rats were allowed to drink tap
water with 2% MgC12 added and were randomly assigned to
receive CsA 15 mg/kg (N = 8) or an identical volume of VH (N =
8) for 14 days. On day 14 BP was measured with a plethysmog-
raphy and the rats were placed in metabolic cages for urine
collection. After 24 hours the animals were anesthetized with
intraperitoneal ketamine and a blood sample was drawn and GFR
was measured.
Analytical methods
Urinary and plasma sodium and potassium were measured by
flame photometry (Instrumentation Laboratories, Lexington,
MA, USA). Urinary and plasma osmolality were measured by
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freezing point (Osmette A; Precision Systems Inc., Natick, MA,
USA). Urinary and plasma creatinine, urinary and plasma mag-
nesium, plasma calcium, urinary alanine aminopeptidase (AAP)
and N-acetyl 13-D-glucosaminidase (NAG) were measured by a
Cobas autoanalyzer (Roche Diagnostics, Hoffmann-La Roche,
Nutley, NJ, USA). Urinary excretion of AAP and NAG were
standardized by urinary creatinine and expressed in IU/g creati-
nine. Serum and urine radioactivity were measured by a Beckman
LS 3801 liquid scintillation counter (Beckman Instruments Inc.,
Palo Alto, CA, USA). The fractional excretion of sodium (FENa),
fractional excretion of potassium (FEK) and fractional excretion
of magnesium (FEMg) were calculated by standard formulas.
Whole blood trough level
Blood was collected in plastic syringes, transferred to metal-free
tubes containing EDTA and was stored at —20°C until deter-
mined by a double sandwich ELISA assay that employed mouse
monoclonal anti-FK 506 antibody (Fujisawa Pharmaceutical Co.,
Osaka, Japan) or a monoclonal radioimmunoassay for CsA
(Incstar Co., Stiliwater, MN, USA) [171.
Urinary nitrate (NO3) /nitrite (NO2) assay
Urinary excretion of the stable nitric oxide (NO) metabolites,
NO2 and NO1 were determined. Urinary NO2 was assayed by the
Griess reaction. Urinary NO1 was estimated by the reduction to
NO2 using nitrate reductase from Aspergillus species (Boehringer
Mannheim, Indianapolis, IN, USA) [18J. The NO1 reduction was
95 to 100% effective. Urinary NO1 excretion was considered the
difference between total NO2 (after reduction) minus initial NO2
values. The results were expressed in js mol/24 hours of urine.
Statistical analysis
Results are presented as mean SEM, and all statistical analyses
were calculated with SYSTAT for Macintosh v. 5.2 (SYSTAT
Inc., Chicago, IL, USA). Comparisons between groups were done
by ANOVA (Kruskal-Wallis test followed by Tukey test). The
level of statistical significance was chosen as P < 0.05.
Results
Physiologic studies
Weight gain was progressive in the three treatment groups of
VH, CsA and FK with no significant difference throughout this
experiment, while despite a pair feeding, animals treated with
RAPA failed to gain as much weight as those of the VH rats with
the difference achieving statistical significance (P < 0.01) at day 14
(Table 1). Hypertension was not observed in any group. CsA
whole blood trough level in CsA-treated animals was 3250 200
ng/ml and FK whole blood trough level in FK-treated animals was
9.8 2.5 nglml at day 14. RAPA levels were unavailable.
Renal function
CsA and FK strikingly decreased urinary excretion of nitric
oxide, RBF and GFR (P < 0.01 vs. VH), whereas RAPA did not
(Table 1). In contrast, all these three drugs caused significant
hypomagnesemia associated with inappropriately high fractional
excretion of magnesium (FEMg), suggesting renal magnesium
wasting (P < 0.01 vs. VH). The fractional excretion of sodium
(FENa) was very low in all groups reflecting the low sodium diet,
and there was no significant difference among the groups (Table
Table 1. Change in body weight, GFR, RBF and blood pressure in the
different groups at day 14
VH CsA FK RAPA
Body wt change 43 6
-
30 7 35 5 9 5"
GFR 1.1 0.1 0.2 0.1" 0.2 0.1" 1.0 0.1
mi/mm/tOO g
RBF 3.3 0.2 1.9 02h 2.0 0.2" 3.1 0.3
mi/mm/tOO g
BP 145±5 139±6 140±5 141±6
mm Hg
UNO 15.2 1.2 9.5 0.6" 10.6 0.8" 19.4 1.7
jz mol/24 hr
Data are mean SEM of eight rats. Abbreviations are: VH, vehicle
control; Body wt, body weight; GFR, inulin clearance (both kidneys);
RBF, renal blood flow (left kidney); BP, systolic blood pressure; UNO,
urinary excretion of N02/N03.
a < 0.05 vs. VH
"P < 0.01 vs. VH
2). Plasma calcium was normal in all groups (VH, CsA, FK,
RAPA: 9.8 0.2, 9.6 0.1, 9.8 0.1, 9.5 0.2 mg/dl,
respectively). Plasma phosphorus and potassium were also normal
in all groups (data not shown). CsA, FK and RAPA caused a
significant increase in the urinary volume (P < 0.05 vs. VH) and
decreases in the urinary osmolality (Usm) and free water reab-
sorption (P < 0.01 and 0.05 vs. VH, respectively), suggesting that
urinary concentrating ability was clearly impaired. The urinary
excretion of AAP was significantly higher in these three immuno-
suppressive agents groups (P < 0.05 vs. VH). There were no
changes in the urinary excretion of NAG in all groups.
When individual animals in all groups were compared by linear
regression, a significant correlation was demonstrated between
the FEMg and U0,,, (N = 64, r = —0.68, P < 0.001). However,
there was no correlation between the FEMg and GFR or RBF.
Magnesium supplementation
CsA whole blood trough level in MgCl2 supplemented rats
treated with CsA was 3270 240 ng/mI and was similar to that of
MgCI2 non-supplemented rats treated with CsA (3250 200
ng/ml). Magnesium supplementation successfully prevented hypo-
magnesemia in CsA-treated animals (plasma magnesium 2.1
0.1 vs. 2.0 0.1 mg./dI in VH treated animals, NS). There was no
increase in the urinary excretion of AAP (46 7 IU/g Cr in CsA
vs. 41 4 IU/g Cr in VH, NS) as well as no decrease in urinary
osmolality between CsA- and VH-treated animals (2600 240
mOsm/kg vs. 2500 180 mOsm/kg, respectively, NS) when
magnesium was supplemented. On the other hand the decrease in
GFR induced by CsA was not modified by magnesium supple-
mentation (0.2 0.1 mI/mm/I 00 gin CsA vs. 1.0 0.1 ml/min/100
g in VH, P < 0.01).
Histologic changes
Table 3 summarized the histologic data of all groups. Tubular
injury was present in rats on CsA, FK and RAPA and consisted of
tubular dilation, tubular atrophy, tubular cast formation and
thickening of the tubular basement membrane (Fig. 1). The injury
score of these groups was significantly higher compared to the VH
control. Tubular injury was supported by observing a significantly
elevated urinary AAP excretion (proximal tubular brush border
Andoh et a!: Acute rapamycin nephrotoxici!y 1113
Table 2. Renal functional parameters in the different groups at day 14
VH CsA FK RAPA
UV mi/24 hr 11.3 1.5 18.1 1.7 17.4 1.5 19.7 21b
Um 2200 25t) 1050 180k' 980 2oo 850 150k'
mOsm/kg
TcW mi/day 58 5 39 4 42 5 40 4
Plasma Na 142 2 143 3 144 3 143 3
mEq/iiter
FEN. %
Plasma Mg
0.05 0.01
1.9 0.03
0.07 0.01
1.1 0.O4'
0.06 0.01
1.0 0.04k
0.07 0.01
1.1 004h
mg/di
FEMS %
Urine AAP
5.5 0.5
41 5
13.7 09b
85 12'
12.5 13h
78 1ft
15.375 8
IU/g Cr
Urine NAG 27 I 25 3 28 2 24 2
IU/g Cr
Data are mean SEM of eight rats. Abbreviations are: VH, vehicle
control; UV, urinaiy volume; U0, urinary osmolality; TcW, free water
reabsorption; FEN., fractional excretion of sodium; FEM5, fractional
excretion of magnesium; AAP, alanine aminopeptidase; NAG, N-acetyl
/3-D-glucosaminidase.
P < 0.05 vs. VH
h P < 0.01 vs. VH
membrane marker enzyme, see above), renal magnesium wasting
and impaired urinary concentrating ability. Nephrocalcinosis was
also prominent at the corticomedullary junction in the animals
treated with these three drugs (Fig. 2).
When individual animals in all groups were compared by linear
regression, a significant correlation could be demonstrated be-
tween the injury score and U0sr, FEMS or urinary AAP (N = 32,
r =
—0.65, P < 0.01; r = 0.75, P < 0.001; r = 0.70, P < 0.001,
respectively).
Discussion
In this study we have compared the acute renal effects of CsA,
FK and RAPA, which have different structures and inhibitory
action on the renal phosphatase calcineurin. This was intended to
provide indirect insight into the issue of whether acute CsA
nephrotoxicity is mediated through inhibition of calcineurin.
Confirming previous studies in our laboratory, rats given CsA or
FK on low salt diet decreased their RBF and GFR [19, 201. Also
these two drugs caused significant hypomagnesemia with inappro-
priately high FEMS, suggesting renal magnesium wasting, and
lesions in the rat kidneys consisting of partial tubular collapse,
vacuolization in proximal tubules and nephrocalcinosis. FK has a
different chemical structure and binding immunophilin from CsA
hut does potently inhibit the phosphatase activity of calcineurin
similar to CsA. RAPA despite being structurally similar to FK and
binding to the same immunophilin, does not inhibit calcineurin
activity or calcineurin-dependent signaling cascades [101. Our
major findings were that while RAPA does not acutely decrease
RBF nor GFR; it does produce profound hypomagnesemia with
high FEMg and the same parenchymal kidney lesions as those
caused by CsA and FK.
Preliminary experimental data indicate that RAPA shows con-
siderably less nephrotoxicity than CsA and FK presumably due to
a different target enzyme for its immunosuppressive effects and by
inference its renal actions [12, 13, 211. Our study supports this
hypothesis since CsA and FK strikingly decrease urinary excretion
of nitric oxide, RBF and GFR (P < 0.01 vs. VH), whereas RAPA
Table 3. Semiquantitative histologic injury score (0 to 3+) in the
different groups at day 14
VH CsA FK RAPA
Tubular injury
Nephrocalcinosis
0.1 0.10 0 1.51.1 0.3k'0.2 1.7 O.4'1.5 03b 1.4 0.31.3 t).4'
Data arc mean SEM of eight rats. Abbreviation is VH, vehicle control.
P < 0.05 vs. VH
hp < 0.01 vs. VH
does not. Recently, nitric oxide (NO) synthase has been found to
be a substrate of calcineurin in vitro [221; its inhibition may, in
part, help to explain the renal dysfunction induced by CsA and
FK. It has been demonstrated that chronic CsA administration
impairs NO production by rat kidney arteries [23, 24]. Experimen-
tal evidence suggests an important role of the decrease of
vasorelaxant mediators in the pathogenesis of the renal vasocon-
striction initiating CsA nephrotoxicity [251. Among these sub-
stances, NO is one of the most prominent [26]. It is produced in
many tissues by a family of NO synthases. A constitutive Ca27
calmodulin-dependent form (cNO synthase) is blocked by the
binding of CsA to calmodulin via the formation of the complex
CsA/cyclophilin [27]. More recently, several groups have found
that acute CsA nephrotoxicity was enhanced by simultaneous NO
blockade with an analogue of L-arginine, whereas significant
improvement in renal dysfunction was achieved by administration
of L-arginine in rats [28—30]. Therefore our data suggest that
glomerular dysfunction induced by CsA may be mediated at least
partly through inhibition of calcineurin and NO biosynthesis.
Lea, Sands and McMahon reported that the inhibition of
Na,K-ATPase activity in mTAL of the kidney by CsA and FK
involves calcineurin, while RAPA does not inhibit either Na,K-
ATPase or calcineurin [11]. It has been suggested that Na,K-
ATPase might have an important role in reabsorption of magne-
sium in the mTAL via secondary active transport [31]. Thus, it
could be hypothesized that CsA reduces Na,K-ATPase activity
by inhibiting calcineurin which induces hypomagnesemia and
other nephrotoxic effects. In this study, CsA treatment in rats
caused a striking increase in the urinary excretion of AAP. This
brush-border enzyme is very sensitive to small renal insults and its
release occurs in early stages of proximal tubular epithelial cell
nephrotoxicity. The lower urinary osmolality and high FEMS in
CsA-treated animals suggest a CsA-mediated physiological defect
in the mTAL. Magnesium supplementation prevented both the
CsA induced tubular abnormalities in our present study. These
results suggest a role of hypomagnesemia in the pathophysiology
of CsA nephrotoxicity. Magnesium is an essential cation, involved
in many enzymatic reactions, as a cofactor to adenosine triphos-
phatase [321. It is critical in energy-requiring metabolic processes,
as well as protein synthesis and anaerobic phosphorylation. Serum
Mg concentration is maintained within a narrow range by the
kidney and small intestine. In addition hypomagnesemia has been
implicated in the pathophysiology of neurotoxicity and essential
hypertension with CsA [5]. Hypomagnesemia is also common in
transplant patients receiving CsA and has been proposed as an
important factor in the pathogenesis of CsA nephrotoxicity [61.
Recent studies suggest that oxygen free radicals may be involved
in tissue injuries produced by magnesium deficiency [33].
In this study, despite a lack of the ability to inhibit calcineurin,
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Fig. 1. Histologic changes in experimental
rapamycin nephrotoxicity in a sodium depleted
rat. Micrograph showing the renal cortex of a
sodium depleted rat given rapamycin 3 mg/kg!
day for two weeks. Most of the cortical tubules
are collapsed. Only a few segments near the
center of the field have normal caliber. Among
the few tubules with patent lumina, most are
lined by flattened epithelium. The interstitium
contains small number of lymphocytes
(Periodic-acid Schiff, ><200).
RAPA clearly induced hypomagnesemia associated with inappro-
priately high fractional excretion of magnesium, and histologic
evidence of partial tubular collapse, vacuolization in proximal
tubules and nephrocalcinosis that were similar to the changes
observed in the CsA and FK treated animals. In this RAPA
model, we found that the histologic changes were accompanied by
tubular functional changes namely decreased medullary concen-
trating ability (U0 and TcW) and increased tubular enzymuria
(AAP) and FEMC, while the kidney injury was not associated with
decreased RBF nor GFR. Since all three drugs induced significant
hypomagnesemia with inappropriately high FEM5, a single mech-
anism of tubular injury distinct from calcineurin inhibition is
possible. The precise mechanism of hypomagnesemia and tubular
injury induced by CsA, FK and RAPA remains to be elucidated,
however, tubular injury can be dissociated from renal hemody-
namic changes as has previously been shown for CsA [201. The
magnesiuria caused by CsA is thought to be associated with a
physiological defect in mTAL, which is the major site for renal
magnesium reabsorption [34]. In our study, when individual
animals in all groups were compared by linear regression, a
significant correlation could be demonstrated between the injury
score and urinary osmolality, FEMg, plasma magnesium or urinary
AAP. Thus, hypomagnesemia and the tubular injury are clearly
associated, although cause and effect has yet to be proven.
The common belief is that the acute form of CsA injury is a
consequence of CsA induced renal vasoconstriction [35]. Accord-
ing to this notion, the arteriolar vasoconstriction with resultant
impairment in RBF leads to acute tubular injury. However, more
recent studies have suggested that there can be a dissociation
between the functional and histologic injuries induced by CsA.
'--:- .a - • j t:'t*fl" :
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Fig. 2. Day 14 rapamycin treated animal with
typical nephrocalcinosis in juxtamedullaiy region,
showing numerous intratubidar caicifications
(Periodic-acid Schifl ><200).
CsA withdrawal led to improved GFR hut the degree of tubular
atrophy and tubulointerstitial fibrosis actually progressed [361.
Blockade of the renin-angiotensin system with losartan or enala-
pril strikingly prevented CsA induced tubulointerstitial fibrosis
without improving GFR [20]. These results suggest that the
mechanism promoting structural injury in chronic CsA nephro-
toxicity can he dissociated from those causing glomerular dysfunc-
tion. Although our RAPA model is an acute model, there may
also be a dissociation between the functional and histological
injuries induced by RAPA.
It is unclear why we found renal histopathologic lesions in
animals treated with RAPA compared to previous reports. One
factor may be the sodium-depletion during which the renin-
angiotensin system is activated. Recently, several investigators
used a reproducible animal model of chronic CsA and FK
nephrotoxicity based on the observation that sodium depletion
exacerbates CsA nephrotoxicity [37— 40]. In this model, CsA
treatment in rats on a low salt diet induced a significant decrease
in GFR and histological changes similar to those described in
patients on long-term CsA therapy. Our salt depletion model
could be used to assess the presence and pathogenesis of any
chronic RAPA induced nephrotoxicity.
One criticism of these animal models are the high doses of the
drugs. The daily CsA dose given in our model (15 mg/kg) is higher
than that employed in human transplantation (4 to 8 mg/kg) [41].
CsA blood levels achieved in this experiment (3250 ng/ml) are
much higher than those the peak levels observed in humans (1000
ng/ml in the acute phase). However, high CsA doses and blood
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levels are also necessary to overcome graft rejection in experi-
mental rodent transplantation and thus the relative therapeutic
window between efficacy and toxic side effects is similar to
humans. The daily FK dose given in our model (6 mg/kg) is 20
times higher than that used in transplant patients (0.15 to 0.3
mg/kg), mainly because bioavailability of FK in rats is much lower
than that of humans [421. However, FK blood levels achieved in
our study (10 ng/ml) arc within the therapeutic window for
humans (10 to 20 ng/m). We could not determine RAPA blood
levels due to technical difficulties. Since RAPA is homologous to
FK in chemical structure and pharmacokinetic properties, it is
assumed that RAPA blood levels are in the same range as FK.
Obviously a simple transposition of the rodent dose-response
relationship to humans is impossible.
In summary, we have demonstrated that CsA and FK strikingly
decrease urinary excretion of nitric oxide, renal blood flow and
GFR, whereas RAPA does not. In contrast, we have shown that
all these three drugs cause significant hypomagnesemia associated
with inappropriately high fractional excretion of magnesium,
suggesting renal magnesium wasting, and lesions in the rat kidneys
consisting of partial tubular collapse, vacuolization in proximal
tubules and nephrocalcinosis accompanied by tubular functional
changes namely decreased medullary concentrating ability (U0,
and TcW) and increased tubular enzymuria (AAP). These studies
suggest that, while these three immunosuppressants all induced
hypomagnesemia associated with renal tubular injury, only the
calcineurin inhibitors (CsA and FK) produced glomerular dys-
function in an acute experimental model of nephrotoxicity. The
mechanism of hypomagnesemia and tubular injury induced by
these immunosuppressive drugs is unclear but seems independent
of calcineurin. On the other hand the mechanism of renal
vasoconstriction might be related to inhibition of calcineurin
phosphatase.
Acknowledgments
This work was supported in part by a grant from the Oregon Health
Sciences Foundation and the Clinical Research Group of Oregon. A
preliminary report of this work was prcsented at the International
Congress of Nephrology, Madrid, Spain in July 1995. We thank Jessie
Lindsley for her technical assistance.
Reprint requests to Takeshi F. Andoh, Ph.D., Division of Nephrology,
Hypertension and Clinical Pharmacology, Mail Code PP262, Oregon Health
Sciences University, 3314 SW US Veterans Hospital Road, Portland, Oregon
97201, USA.
References
I. KAHAN BD: Cyclosporine. N EngI J Med 321:1725—1738, 1989
2. FEUTREN G, MIIIATSCH MJ: Risk factors for cyclosporineinduced
nephropathy in patients with autoimmune diseases. International
Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
N Engl J Med 326:1654—1660, 1992
3. Miss BD, SIHLEY R, NEWTON L, TOMLANOVICI-I SJ, Bosiuos C,
STINSON E, LIJETSCHER JA, WHITNEY DJ, KRASNY D, COPLON NS,
PERLROTH MG: The long-term course of cyclosporine-associated
chronic nephropathy. Kidney mt 33:590—600, 1988
4. BENNETT WM, BURDMANN EA, ANDOII TF, HoUGI-IT0N DC, LINDs-
I.EY J, ELZINGA LW: Nephrotoxicity of immunosuppressive drugs.
Nephrol Dial Transplant 9(Suppl 4):141—145, 1994
5. AL KIILJRSANY I, THOMAS TH, HARRISON K, WILKINSON R: Reduced
erythrocyte and leukocyte magnesium is associated with cyclosporin
treatment and hypertension in renal transplant patients. (see com-
ments) Nephrol Dial Transplant 7:25 1—255, 1992
6. Nozue T, KOBAYASHI A, KODAMA T, UEMASU F, ENDOH H, SAKO A,
TAKAGI Y: Pathogenesis of cyclosporine-induced hypomagnesemia.
JPediatr 120:638—640, 1992
7. STARZI. TE, TODD 5, FUND J, DEMETRIS AJ, VENKATARAMMAN R,
JAIN A: FK 506 for liver, kidney, and pancreas transplantation. Lancet
2:1000—1004, 1989
8. MURGIA MG, JORDAN S, KAHAN BD: The side effect profile of
sirolimus—A phase I study in quiescent cyclosporine-prednisone.
treated renal transplant patients. Kidney mt 49:209—216, 1996
9. Uu J, FARMER JDJ, LANE WS, FRIEDMAN J, WEISSMAN I, SCHREIBER
SL: Calcineurin is a common target of cyclophilin-cyclosporin A and
FKBP-FK506 complexes. Cell 66:807—815, 1991
10. FRUMAN DA, KLEE CB, BIERER BE, BURAKOFF SJ: Calcineurin
phosphatase activity in T lymphocytes is inhibited by FK 506 and
cyclosporin A. Proc Nat! Acad Sci USA 89:3686—3690, 1992
11. LEA JP, SANDS JM, MCMAHON SJ, TUMLIN JA: Evidence that the
inhibition of Na,K-ATPase activity by FK506 involves calcineurin.
Kidney mt 46:647—652, 1994
12. RYFFEL B, WEBER E, MIHATSCH MJ: Nephrotoxicity of immunosup-
pressants in rats: Comparison of macrolides with cyclosporin. Exp
Nephrol 2:324—333, 1994
13. DIJOSEPH JF, SIIARMA RN, CHANG JY: The effect of rapamycin on
kidney function in the Sprague-Dawley rat. Transplantation 53:507—
513, 1992
14. GOTO 5, STEPKOWSKI SM, KAHAN BD: Effect of FK 506 and cyclo-
sporine on heart allograft survival in rats. Transplant Proc 23:529—530,
1991
15. STEPKOWSKI SM, CHEN H, DALOZE P, KAHAN BD: Rapamycin, a
potent immunosuppressive drug for vascularized heart, kidney, and
small bowel transplantation in the rat. Transplantation 5 1:22—26, 1991
16. INAMURA N, NAKAHARA K, KIN0 T, GoTo T, AOKI H, YAMAGUCHI I,
KOHSAKA M, OCHIAI T: Prolongation of skin allograft survival in rats
by a novel immunosuppressive agent, FK506. Transplantation 45:206—
209, 1988
17. TAMURA K, KOBAYASHI M, HASHIMOTO K, KOJIMA K, NAGASE K: A
highly sensitive method to assay FK-506 levels in plasma. Transplant
Proc 19(Suppl 6):23—29, 1987
18. CONRAD KP, J0FFE GM, KRUSZYNA H, KRUSZYNA R, ROCHELLE LG,
SMITH RP, CHAVEZ JE, MOSHER MD: Identification of increased
nitric oxide biosynthesis during pregnancy in rats. FASEB J 7:566—571,
1993
19. ANDOH TF, BURDMANN EA, LINDSLEY J, HOUGHTON DC, BENNETT
WM: Functional and structural characterisics of experimental FK506
nephrotoxicity. Clin Exp Pharinacol Physiol 22:646—654, 1995
20. BURDMANN EA, ANDOH TF, NAST CC, EVANS A, CONNOR BA,
COFFMAN TM, LINDSLEY 1, BENNETT WM: Prevention of experimental
cyclosporine-induced interstitial fibrosis by losartan and enalapril.
Am J Physiol 269:F491—F499, 1995
21. KAHAN BD, CHANG JY, SEHGAL SN: Preclinical evaluation of a new
potent immunosuppressive agent, rapamycin. Transplantation 52:185—
191, 1991
22. DAWSON TM, STEINER JP, DAWSON VL, DINERMAN JL, UHL GR,
SNYDER SH: Immunosuppressant FK506 enhances phosphorylation of
nitric oxide synthase and protects against glutamate neurotoxicity.
(see comments) Proc NatlAcad Sci USA 90:9808—9812, 1993
23. GALLEGO MJ, GARCIA VILLALON AL, LOPEZ FARRE AJ, GARCIA JL,
GARRON MP, CASADO 5, HERNANDO L, CARAMELO CA: Mechanisms
of the endothelial toxicity of cyclosporin A. Role of nitric oxide,
cGMP, and Ca2t Circ Res 74:477—484, 1994
24. DIEDERICH D, YANE Z, LUSCHER TF: Chronic cyclosporine therapy
impairs endothelium-dependent relaxation in the renal artery of the
rat. JAm Soc Nephrol 2:1291—1297, 1992
25. ROULLET JB, XUE H, MCCARRON DA, 1-JOLCOMB S, BENNETT WM:
Vascular mechanisms of cyclosporin-induced hypertension in the rat.
J Clin Invest 93:2244—2250, 1994
26. MONCADA 5, REES DD, SCHULZ R, PALMER RM: Development and
mechanism of a specific supersensitivity to nitrovasodilators after
inhibition of vascular nitric oxide synthesis in vivo. Proc NatlAcad Sci
USA 88:2166—2170, 1991
27. SCHREIBER SL: Immunophilin-sensitive protein phosphatase action in
cell signaling pathways. Cell 70:365—368, 1992
28. GALLEGO MJ, LOPEZ FARRE A, RIESCO A, MONTON M, GRANDES SM,
BARAr A, HERNANDO L, CASADO 5, CARAMEI,O CA: Blockade of
Andoh et at: Acute rapamycin nephrotoxiciiy 1117
endothelium-dependent responses in conscious rats by cyclosporin A:
Effect of L-arginine. Am J Physiol 264:H708—H714, 1993
29. Dc NIc0LA L, THOMSON SC, WEAD LM, BROWN MR, GABBAI FB:
Arginine feeding modifies cyclosporine nephrotoxicity in rats. J C/in
Invest 92:1859—1865, 1993
30. GARDNER MP, HOUGHTON DC, ANDOH TF, LINDSLEY J, BENNETT
WM: Clinically relevant doses and blood levels produce experimental
cyclosporine nephrotoxicity when combined with nitric oxide inhibi-
tion. Transplantation (in press)
31. SENEY FDJ, MARVER D: Protein intake and cation transport in the
loop of Henle. fLab C/in Med 114:587—594, 1989
32. AL GuAMDI SM, CAMERON EC, SUTTON RA: Magnesium deficiency:
Pathophysiologic and clinical overview. Am J Kidney Dis 24:737—752,
1994
33. Rock E, ASTIER C, LAB C, VIGNON X, GUEUX E, M0TrA C,
RAYSSIGUIER Y: Dietary magnesium deficiency in rats enhances free
radical production in skeletal muscle. J Nutr 125:1205—1210, 1995
34. QUAMME GA: Control of magnesium transport in the thick ascending
limb. Am J Physiol 256:F197—F210, 1989
35. CONTE G, DAL CANTON A, SARBATINI M, NAPODANO P, DE NICOLA L,
GIGUOTTI G, FuIAN0 G, TESTA A, EsPosiTo C, RUSSO D, ANDREUCCI
VE: Acute cyclosporine renal dysfunction reversed by dopamine
infusion in healthy subjects. Kidney mt 36:1086—1092, 1989
36. ELZINGA LW, ROSEN 5, BENNETT WM: Dissociation of glomerular
filtration rate from tubulointerstitial fibrosis in experimental chronic
cyclosporine nephropathy: Role of sodium intake. JAm Soc Nephrol
4:214—221, 1993
37. YOUNG BA, BURDMANN EA, JOHNSON Ri, ANDOH T, BENNETT WM,
COUSER WG, ALPERS CE: cyclosporine A induced arteriolopathy in a
rat model of chronic cyclosporine nephropathy. Kidney mt 48:431—
438, 1995
38. ANDOH TF, BURDMANN EA, LINDSLEY J, HOUGHTON DC, BENNETT
WM: Enhancement of FK506 nephrotoxicity by sodium depletion in
an experimental rat model. Transplantation 57:483—489, 1994
39. KON V, HUNLEY TE, FOGO A: Combined antagonism of endothelin
A/B receptors links endothelin to vasoconstriction whereas angioten-
sin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in
rats. Transplantation 60:89—95, 1995
40. ROSEN S, GREENFELD Z, BREZIS M: Chronic cyclosporinc-induced
nephropathy in the rat. A medullary ray and inner stripe injury.
Transplantation 49:445—45 2, 1990
41. JORDAN ML, SHAPIRO R, VIvAS CA, SCANTLEBURY VP, DARRAS FS,
CARRIERI G, MCCAULEY J, DEMETRIS AJ, RANDHAWA P, JENSEN C,
HAKALA TR, FUNG JJ, STARZI. TE: FK 506 salvage of renal allografts
with ongoing rejection failing cyclosporine immunosuppression.
Transplant Proc 25:638—640, 1993
42. JAPANESE STUDY OF FK 506 ON KIDNEY 'rRANSPLANTATION: Results of
late phase 11 study. Transplant Proc 25:649—654, 1993
